Startseite » Forschung » Studien Finasterid » Traish et al. (2015). Adverse effects of 5α-reductase inhibitors (Review) (What do we know, don't know, and need to know )
Traish et al. (2015). Adverse effects of 5α-reductase inhibitors (Review) [Beitrag #346141] :: Fri, 25 September 2015 12:14 Zum vorherigen Beitrag gehen
Traish et al. haben im August eine Review zu den Nebenwirkungen von Fin/Dut herausgebracht.
Ich hoffe inständig, dass es methodisch sauberer ist als seine bisherigen Primärstudien.
(bei Reviews kann man allerdings auch weniger falsch machen)

Wie auch immer: Das Paper gibt's es jetzt nicht mehr nur hinter einer Paywall, sondern auch im Volltext im Netz.
Habe es aus Zeitgründen noch nicht lesen können, bin aber zugegeben gespannt Cool

http://link.springer.com/article/10.1007/s11154-015-9319-y
https://cld.pt/dl/download/424c0a47-6954-4b35-90d8-4d2379d06dde/MyPapers04/ay957439273.pdf

Abstract
Steroids are important physiological orchestrators of endocrine as well as peripheral and central nervous system functions. One of the key processes for regulation of these molecules lies in their enzymatic processing by a family of 5α-reductase (5α-Rs) isozymes. By catalyzing a key rate-limiting step in steroidogenesis, this family of enzymes exerts a crucial role not only in the physiological control but also in pathological events. Indeed, both 5α-R inhibition and supplementation of 5α-reduced metabolites are currently used or have been proposed as therapeutic strategies for a wide array of pathological conditions. In particular, the potent 5α-R inhibitors finasteride and dutasteride are used in the treatments of benign prostatic hyperplasia (BPH), as well as in male pattern hair loss (MPHL) known as androgenetic alopecia (AGA). Recent preclinical and clinical findings indicate that 5α-R inhibitors evoke not only beneficial, but also adverse effects. Future studies should investigate the biochemical and physiological mechanisms that underlie the persistence of the adverse sexual side effects to determine why a subset of patients is afflicted with such persistence or irreversible adverse effects. Also a better focus of clinical research is urgently needed to better define those subjects who are likely to be adversely affected by such agents. Furthermore, research on the non-sexual adverse effects such as diabetes, psychosis, depression, and cognitive function are needed to better understand the broad spectrum of the effects these drugs may elicit during their use in treatment of AGA or BPH. In this review, we will summarize the state of art on this topic, overview the key unresolved questions that have emerged on the pharmacological targeting of these enzymes and their products, and highlight the need for further studies to ascertain the severity and duration of the adverse effects of 5α-R inhibitors, as well as their biological underpinnings.

...es kann also ordentlich ausgerastet werden Wink




Fin seit 2009 (1.25mg/Woche); Minox seit 2011; Ket seit 2012 (1%/Tag)
Abgesetzt: Dut 2011-2017 (0.05mg/Woche); RU 2014-2017 (3%/Tag)

Den Beitrag einem Moderator melden

 Eine private Nachricht an diesen Benutzer verschicken  
 
 
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Vorheriges Thema: Metaanalyse zur Qualität von 34 klinischen Studien (Finasterid)
Nächstes Thema: PFS auf Italienisch
Gehe zum Forum:
  


aktuelle Zeit: Fri Apr 19 14:30:17 CEST 2024

Insgesamt benötigte Zeit, um die Seite zu erzeugen: 0.04752 Sekunden
Partner Hairforlife FUE EUROPE